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Effects of High-dose Vitamin E Supplementation on Markers 
of Cardiometabolic Risk and Oxidative Stress in Patients 
with Diabetic Nephropathy
A Randomized Double-blinded Controlled Trial
Esmat Aghadavod,1 Alireza Soleimani,2 Gholamali Hamidi,3 
Fariba Keneshlou,4 Akbar Heidari,1 Zatollah Asemi1
Introduction. Patients with diabetic nephropathy (DN) may benefit 
from vitamin E’s antilipid and antioxidant activities. This study 
aimed to evaluate the effects of high-dose vitamin E supplementation 
on markers of cardiometabolic risk and oxidative stress in patients 
with DN.
Materials and Methods. This randomized controlled trial was 
carried out on 54 patients with DN that were randomly divided 
into 2 groups to receive vitamin E supplement (800 IU/d) or 
placebo for 12 weeks. Fasting blood samples were obtained at 
baseline and after the 12-week intervention to determine markers 
of cardiometabolic risk and oxidative stress.
Results. Vitamin E supplementation, compared with the placebo, 
resulted in a significant reduction in serum total cholesterol 
(-14.3 ± 29.9 mg/dL versus -0.8 ± 13.1 mg/L, P = .03), low-density 
lipoprotein cholesterol (-16.4 ± 28.5 mg/dL versus 0.1 ± 17.2 mg/L, 
P = .01), and ratio of total cholesterol to high-density lipoprotein 
cholesterol ratio (-0.5 ± 0.7 versus 0.1 ± 0.5, P = .001), and a significant 
elevation in vitamin E levels (39.7 ± 12.4 nmol/mL versus -0.5 ± 1.3 
nmol/mL, P < .001) and high-density lipoprotein cholesterol levels 
(1.4 ± 3.7 versus -2.1 ± 5.1 mg/L, P = .006). It also resulted in a 
significant elevation in plasma glutathione levels.
Conclusions. Our study demonstrated that high-dose vitamin 
E supplementation for 12 weeks had favorable effects on lipid 
profile and glutathione levels of patients with DN, except for 
triglycerides, very low-density lipoprotein cholesterol, nitric oxide, 
and total antioxidant capacity levels.
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INTRODUCTION
D y s l i p i d e m i a  i s  a  m e t a b o l i c  d i s o r d e r 
characterized by diverse lipid profiles, such as 
hypertriglyceridemia, hypercholesterolemia, and 
decreased high-density lipoprotein cholesterol 
(HDLC) levels,1 and is emerging as an independent 
risk factor for the development of kidney disease 
in diabetic nephropathy (DN).2,3 Previous studies 
strongly suggested that hyperlipidemia could 
result in glomerulosclerosis and tubulointerstitial 
fibrosis and induce renal injury by promoting the 
intrarenal generation of reactive oxygen species 
and free radicals and by glomerular infiltration of 
monocytes and macrophages.4 In addition, increased 
biomarkers of oxidative stress are associated with 
the development of late diabetic complications.5
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Antioxidants administration has demonstrated 
a beneficial role in the prevention of the diabetic 
complications. Diabetes mellitus (DM) forms a 
good model of dyslipidemia and chronic oxidative 
damage, and thus it is a particularly suitable for 
antioxidant supplementation.6 In an animal study, 
supplementation with d-α-tocopherol significantly 
improved insulin resistance, serum triglycerides, 
very low-density lipoprotein cholesterol (VLDL), 
and malondialdehyde concentrations.7 Earlier, it 
was reported that d-α-tocopherol could regulate 
gene expression related to lipid metabolism and 
peroxisome proliferator activated-receptor-γ.6,8 
Vitamin E supplementation for 16 weeks among 
maintenance hemodialysis patients significantly 
improved lipid profiles.9 Furthermore, vitamin 
E supplementation at dosages of 200 IU/d and 
300 IU/d for 4 months provided marked benefits 
in reducing oxidative stress concentrations and 
improving lipid profiles in women with metabolic 
syndrome.10 However, vitamin E supplementation 
for 120 days in orchiectomized rats significantly 
reduced oxidative stress without modulating lipid 
profiles or inflammatory response.11
Considering that the pathogenesis of DN 
may be correlated with increased markers of 
cardiometabolic risk and oxidative stress and 
since there is evidence that vitamin E intake has 
antilipid and antioxidant actions, we hypothesized 
that high-dose vitamin E supplementation might 
help DN population to control their markers of 
cardiometabolic risk and oxidative stress. This 
investigation was aimed to evaluate the effects of 
high-dose vitamin E supplementation on markers 
of cardiometabolic risk and oxidative stress among 
DN patients.
MATERIALS AND METHODS
Participants
This randomized double-blinded placebo-
controlled clinical trial was conducted on 54 patients 
with DN, aged 40 to 85 years old, referred to Shahid 
Beheshti Clinic in Kashan, Iran, from May 2017 to 
August 2017. We defined DN as diabetic kidney 
disease with a proteinuria level greater than 0.3 
g/24 h, with or without circulating levels of serum 
creatinine.12 Patients matching any of the following 
criteria were excluded: vitamin E supplementation 
within the past 3 months, pregnancy, and chronic 
liver disease (abnormal liver enzymes levels). 
Based on suggested formula for clinical trials, we 
calculated that we needed 23 participants in each 
group considering a type 1 error of 0.05, a type 2 
error of 0.20, and 3.5 mg/dL as standard deviation 
and 2.9 mg/dL as the distinction in mean of low-
density lipoprotein cholesterol (LDLC) level as 
the key variable.13 Assuming 4 dropouts in each 
group, the final sample size was determined to be 
27 participants per group.
Ethics
This study was conducted in accordance with 
the Declaration of Helsinki and written informed 
consent was taken from all of the participants. 
The research protocol was approved by the 
research ethics committee of Kashan University 
of Medical Sciences and was registered by the 
Iranian Registry of Clinical Trials (http://www.
irct.ir; IRCT201706055623N117).
Study Design
All of the participants were stratified based on 
sex, number and type of hypoglycemic medications, 
duration of DM, body mass index (BMI), and age. 
They were randomly allocated into 2 groups to 
take either 800 mg/d of vitamin E supplement or 
placebo (n = 27 in each group) for 12 weeks. Vitamin 
E supplements and placebos (similar in shape and 
size to vitamin E capsule) were manufactured by 
Zahravi Pharmaceutical Company (Tabriz, Iran). 
Randomization and allocation into 2 groups were 
done using a random number table by one of the 
investigators who had no clinical involvement in 
the research. Compliance to the intake of vitamin 
E supplement and placebo was assessed by vitamin 
E levels using an enzyme-linked immunosorbent 
assay method.
Assessment of Anthropometric Measures
Weight and height of the participants were 
determined in an overnight fasting status using 
a standard scale (Seca, Hamburg, Germany) at 
baseline and after the 12-week treatment. Body 
mass index was calculated as weight in kilograms 
divided by squared height in meters.
Assessment of Outcomes
Lipid profile was considered as the primary 
outcome, and biomarkers of oxidative stress 
were considered as the secondary outcomes. Ten 
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milliliter fasting blood samples were collected 
at baseline and after the 12-week intervention 
at Kashan Reference Laboratory, Kashan, Iran. 
Serum vitamin E levels were assessed by an 
enzyme-linked immunosorbent assay kit (Crystal 
Day, Shanghai, China) with inter- and intra-assay 
coefficient variances of 5.3 and 6.8%, respectively. 
Enzymatic kits (Pars Azmun, Tehran, Iran) were 
applied to evaluate serum triglycerides, VLDLC, 
total cholesterol, LDLC, HDLC, and fasting plasma 
glucose concentrations. All inter- and intra-assay 
coefficient variances for lipid profile and fasting 
plasma glucose were less than 5%. The plasma 
nitric oxide (NO) levels were determined using 
the Griess method.14 The plasma total antioxidant 
capacity (TAC) level was assessed using the method 
of ferric-reducing antioxidant power developed 
by Benzie and Strain.15 Total glutathione (GSH) 
was determined using the method of Beutler et 
al.16 Malondialdehyde levels were determined 
using the thiobarbituric acid reactive substances 
spectrophotometric test.17 Coefficient variances for 
plasma NO, TAC, glutathione, and malondialdehyde 
were lower than 5%, respectively. Hemoglobin 
A1c levels in the whole blood were quantified by 
Glycomat kit (BiocodeHycel, Massy, France) using 
the method of exchange chromatography.
Statistical Analysis
To evaluate normal distribution of the variables 
in the study, we applied the Kolmogrov-Smirnov 
test. The analyses were conducted based on 
intention-to-treat principle. To detect differences in 
anthropometric measures as well as in macro- and 
micro-nutrient intakes between the two groups, 
we applied independent samples Student t test. To 
determine the effects of vitamin E supplementation 
on biochemical parameters, we used the 1-way 
repeated measures analysis of variance. Adjustment 
for confounding variables was done by the analysis 
of covariance using general linear models. A P 
value less than .05 was considered significant. All 
statistical analyses were done using the Statistical 
Package for Social Science version 18 (SPSS Inc., 
Chicago, Illinois, USA).
RESULTS
Among the participants of each group, 3 withdrew 
from the study due to personal reasons (Figure). 
Finally, 48 patients (24 in the vitamin E group 
Summary of patient flow diagram.
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and 24 in the placebo group) completed the trial. 
However, we did the analysis based on intention-
to-treat principle, and all 54 patients (27 patients 
in each group) were included in the final analysis. 
There were no significant differences between the 
two groups in the mean age, height, weight, or 
BMI at baseline and after the trial, or in duration 
of DM, using antidiabetic and antilipidemic 
medication (Table 1).
Based on the 3-day dietary records obtained 
throughout the trial, we found no signiﬁcant 
difference in the mean dietary macro- and micro-
nutrient intakes (data not shown). After the 12-
week intervention, compared with the placebo, 
vitamin E supplementation resulted in a significant 
reduction in serum total cholesterol (-14.3 ± 29.9 
mg/dL versus -0.8 ± 13.1 mg/L, P = .03), LDLC 
(-16.4 ± 28.5 mg/dL versus 0.1 ± 17.2 mg/L, P = .01), 
and total cholesterol-HDLC ratio (-0.5 ± 0.7 versus 
0.1 ± 0.5, P = .001), and a significant elevation in 
vitamin E levels (39.7 ± 12.4 nmol/mL versus 
-0.5 ± 1.3 nmol/mL, P < .001) and HDLC levels 
(1.4 ± 3.7 versus -2.1 ± 5.1 mg/L, P = .006; Table 2). 
In addition, vitamin E supplementation resulted 
in a significant elevation in plasma glutathione 
levels (72.7 ± 160.8 µmol/L versus -42.8 ± 127.8 
µmol/L, P = .005) compared with the placebo. 
Supplementation with vitamin E had no significant 
effects on other lipid profiles and biomarkers of 
oxidative stress compared with the placebo.
There was a significant difference in baseline 
levels of HDLC (P = .001) between the two groups. 
Therefore, we adjusted the analysis for baseline of 
biochemical variables, age, and baseline BMI. When 
we controlled the analysis for baseline values of 
biochemical variables, age and baseline BMI, the 
difference in changes in HDLC between the two 
groups became nonsignificant (P = .15), while other 
findings did not change (Table 3).
DISCUSSION
In the current study, we assessed the effects of 
high-dose vitamin E supplementation on markers 
of cardiometabolic risk and oxidative stress among 
patients with DN. We found that high-dose 
vitamin E supplementation for 12 weeks among 
DN patients had favorable effects on lipid profiles 
and glutathione levels except triglycerides, VLDLC, 
Characteristic Placebo Group(n = 27)
Vitamin E Group
(n = 27) P
Sex
Male 8 (29.6) 8 (29.6) > .99
Female 19 (70.4) 19 (70.4)
Age, y 64.5 ± 9.2 62.2 ± 9.8 .38
Height, cm 163.8 ± 6.8 161.6 ± 8.7 .31
Body weight, kg
Baseline 83.3 ± 16.1 80.7 ± 14.1 .52
At the end of trial 83.8 ± 16.2 80.9 ± 13.9 .47
Body mass index, kg/m2
Baseline 31.1 ± 6.1 30.9 ± 4.7 .88
At the end of trial 31.2 ± 6.0 30.9 ± 4.6 .82
Smoking 2 (7.4) 2 (7.4) > .99
Diabetes mellitus
Type 1 3 (11.1) 3 (11.1) > .99
Type 2 24 (88.9) 24 (88.9)
Duration of diabetes, y 16.1 ± 3.3 16.4 ± 2.8 .72
Insulin therapy 22 (81.5) 21 (77.8) .73
Antidiabetic medication
Monotherapy 3 (11.1) 3 (11.1)
Combination therapy 24 (88.9) 24 (88.9) > .99
Antilipid medication
Monotherapy 16 (59.3) 17 (63.0)
Combination therapy 3 (11.1) 4 (14.8) .79
Hypertension 25 (92.6) 25 (92.6) > .99
Table 1. Characteristics of Study Participants*
*Data are mean ± standard deviation or frequency (percentage).
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NO, and TAC. To our knowledge, this is the first 
report of high-dose vitamin E supplementation 
on markers of cardiometabolic risk and oxidative 
stress in patients with DN.
Diabetic nephropathy is associated with metabolic 
disturbances, inflammation, and oxidative stress.18 
We found that taking vitamin E supplements for 
12 weeks by patients with DN were correlated 
with a significant reduction in serum total 
cholesterol, LDLC, and total cholesterol-HDLC, and 
a significant elevation in HDLC levels compared 
with the placebo, but did not affect triglycerides 
and VLDLC levels. Supporting our study, vitamin 
E supplementation for 4 months in a hemodialysis 
population led to a significant reduction in total 
cholesterol and LDLC concentrations, but did not 
affect other lipid fractions.19 In addition, vitamin 
E plus symbiotic supplementation was beneficial 
in lowering triglycerides, total cholesterol, and 
LDLC among patients with nonalcoholic fatty 
liver disease.13 Vitamin E and omega-3 fatty acids 
cosupplementation for 12 weeks in women with 
polycystic ovary syndrome significantly improved 
lipid profiles.20 Cosupplementation of 150 mg 
of vitamin E, 200 mg of vitamin C, 200 mg of 
magnesium, and 30 mg of zinc for 3 months in 
patients with type 2 DM significantly increased 
HDLC and apo A1, but did not affect other lipid 
profiles.21 However, vitamin E supplementation 
at  a  dose of  400 IU/d for 8  weeks did not 
influence total cholesterol or LDLC levels in 
hypercholesterolemic patients receiving lovastatin 
or simvastatin.22 Diabetic nephropathy is strongly 
linked with dyslipidemia in diabetic patients.23 
Previous studies have found even more robust 
lipid disorders correlated with nephropathy than 
with cardiovascular disease.24 Vitamin E intake 
inhibits signal transduction pathways including 
protein kinase C.25 Vitamin E supplementation 
may stimulate the proliferator activated-receptor-γ 
transduction pathway,26 which in turn decrease 
cholesterol levels.
The current study demonstrated that vitamin 
E supplementation among patients with DN 
were associated with a significant increase in 
plasma glutathione levels compared with the 
placebo, but did not increase plasma TAC and 
NO concentrations. In agreement with our study, 
vitamin E supplementation at a dose of 600 mg/d 
for 3 months ameliorated oxidative stress through 
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increasing levels of glutathione in patients with 
type 1 DM.27 In addition, vitamins E and C 
cosupplementation with exercise protected against 
fibromyalgia-induced oxidative stress through 
upregulation of an antioxidant redox system in 
the plasma and erythrocytes of individuals with 
fibromyalgia.28 Supplementation with combined 
vitamin E (400 IU/d) and vitamin C (500 mg/d) for 
2 months significantly decreased lipid peroxidation 
and strengthened the antioxidant defense system 
in patients with cardiovascular disease through 
significant increases in superoxide dismutase and 
glutathione peroxidase activity.29 Furthermore, 
in another study, vitamin E supplementation 
significantly improved biomarkers of oxidative 
stress.30 However, no significant differences 
were  observed in  erythrocyte  superoxide 
dismutase and glutathione peroxidase activities, 
glutathione, and plasma TAC, lipid peroxides 
and glutathione peroxidase activity following the 
supplementation of vitamin E at a dosage of 400 
IU twice a day for 8 weeks in patients with chronic 
obstructive pulmonary disease.31 Overproduction 
of intracellular reactive oxygen species and free 
radicals contributes to several microvascular and 
macrovascular complications of DN, and increase 
the production of inflammatory cytokines.32
This study had few limitations. First, sample 
size was low. Future studies with longer duration 
of the intervention and a larger sample size are 
needed to confirm the validity of our findings. 
Second, we did not evaluate the effects of vitamin 
E supplementation on the mean daily proteinuria 
and gene expression related to biomarkers of 
inflammation and oxidative stress.
CONCLUSIONS
Our study demonstrated that high-dose vitamin 
E supplementation for 12 weeks among DN 
patients had favorable effects on lipid profiles 
and glutathione levels except for triglycerides, 
VLDLC, NO, and TAC.
ACKNOWLEDGEMENTS
The present study was supported by a grant 
from the Vice-chancellor for Research, Kashan 
University of Medical Sciences, Iran.
CONFLICTS OF INTEREST
None declared.
REFERENCES
1. Jain KS, Kulkarni RR, Jain DP. Current drug targets 
for antihyperlipidemic therapy. Mini Rev Med Chem. 
2010;10:232-62.
2. Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums 
G, Ekinci EI. Clinical predictive factors in diabetic kidney 
disease progression. J Diabetes Investig. 2017;8:6-18.
3. Russo GT, De Cosmo S, Viazzi F, et al. Plasma 
Triglycerides and HDL-C levels predict the development of 
diabetic kidney disease in subjects with type 2 diabetes: 
The AMD Annals Initiative. Diabetes Care. 2016;39:2278-
87.
4. Lewis D, Wanner C. Diabetes: Should we use fibrates in 
patients with diabetes and mild CKD? Nat Rev Nephrol. 
2012;8:201-2.
5. Sha J, Sui B, Su X, Meng Q, Zhang C. Alteration of 
oxidative stress and inflammatory cytokines induces 
apoptosis in diabetic nephropathy. Mol Med Rep. 
2017;16:7715-23.
6. Siddiqui S, Ahsan H, Khan MR, Siddiqui WA. Protective 
effects of tocotrienols against lipid-induced nephropathy 
in experimental type-2 diabetic rats by modulation in TGF-
beta expression. Toxicol Appl Pharmacol. 2013;273:314-24.
Parameter Placebo Group(n = 27)
Vitamin E Group
(n = 27) P
Vitamin E, nmol/mL -0.3 ± 1.7 39.6 ± 1.7 < .001
Triglycerides, mg/dL 4.2 ± 13.6 5.4 ± 13.6 .95
Very low-density lipoprotein cholesterol, mg/dL 0.9 ± 2.7 1.1 ± 2.7 .95
Total cholesterol, mg/dL -0.9 ± 4.1 -14.2 ± 4.1 .02
Low-density lipoprotein cholesterol, mg/dL -0.6 ± 4.3 -15.7 ± 4.3 .01
High-density lipoprotein cholesterol, mg/dL -1.3 ± 0.9 0.6 ± 0.9 .15
Ratio of total cholesterol to high-density lipoprotein cholesterol -0.008 ± 0.1 -0.4 ± 0.1 .03
Nitric oxide, µmol/L 3.2 ± 1.8 0.7 ± 1.8 .33
Total antioxidant capacity, mmol/L 50.5 ± 53.1 71.5 ± 53.1 .78
Glutathione, µmol/L -42.3 ± 28.6 72.2 ± 28.6 .007
Table 3. Adjusted Changes in Metabolic Variables in Patients With Diabetic Nephropathy That Received Either Vitamin E Supplement or 
Placebo*
*Data are mean ± standard deviation or frequency (percentage). Results were obtained from the analysis of covariance test adjusted for baseline 
values plus age and baseline body mass index.
Vitamin E and Patients with Diabetic Nephropathy—Aghadavod et al
162 Iranian Journal of Kidney Diseases | Volume 12 | Number 3 | May 2018
7. Kim DY, Kim J, Ham HJ, Choue R. Effects of d-alpha-
tocopherol supplements on lipid metabolism in a high-fat 
diet-fed animal model. Nutr Res Pract. 2013;7:481-7.
8. Zhang Y, Li Y, Liang X, Gao J. Effects of dietary vitamin 
E supplementation on growth performance, fatty 
acid composition, lipid peroxidation and peroxisome 
proliferator-activated receptors (PPAR) expressions in 
juvenile blunt snout bream Megalobrama amblycephala. 
Fish Physiol Biochem. 2017;43:913-22.
9. Daud ZA, Tubie B, Sheyman M, et al. Vitamin 
E tocotrienol supplementation improves lipid profiles in 
chronic hemodialysis patients. Vasc Health Risk Manag. 
2013;9:747-61.
10. Wang Q, Sun Y, Ma A, Li Y, Han X, Liang H. Effects of 
vitamin E on plasma lipid status and oxidative stress in 
Chinese women with metabolic syndrome. Int J Vitam Nutr 
Res. 2010;80:178-87.
11. Deyhim F, Gonzales C, Garcia C, et al. Vitamin E does not 
modulate plasma lipid profile or C-reactive protein despite 
suppressing oxidative stress in orchiectomized rats. J Med 
Food. 2007;10:559-62.
12. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, 
Caramori ML, Zelmanovitz T. Diabetic nephropathy: 
diagnosis, prevention, and treatment. Diabetes Care. 
2005;28:164-76.
13. Ekhlasi G, Kolahdouz Mohammadi R, Agah S, et al. Do 
symbiotic and Vitamin E supplementation have favorite 
effects in nonalcoholic fatty liver disease? A randomized, 
double-blind, placebo-controlled trial. J Res Med Sci. 
2016;21:106.
14. Tatsch E, Bochi GV, Pereira Rda S, et al. A simple and 
inexpensive automated technique for measurement of 
serum nitrite/nitrate. Clin Biochem. 2011;44:348-50.
15. Benzie IF, Strain JJ. The ferric reducing ability of plasma 
(FRAP) as a measure of “antioxidant power”: the FRAP 
assay. Anal Biochem. 1996;239:70-6.
16. Beutler E, Gelbart T. Plasma glutathione in health and 
in patients with malignant disease. J Lab Clin Med. 
1985;105:581-4.
17. Janero DR. Malondialdehyde and thiobarbituric acid-
reactivity as diagnostic indices of lipid peroxidation 
and peroxidative tissue injury. Free Radic Biol Med. 
1990;9:515-40.
18. Joven MH, Anderson RJ. Update on blood pressure 
control and renal outcomes in diabetes mellitus. Curr Diab 
Rep. 2015;15:613.
19. Mafra D, Santos FR, Lobo JC, et al. Alpha-tocopherol 
supplementation decreases electronegative low-density 
lipoprotein concentration [LDL(-)] in haemodialysis 
patients. Nephrol Dial Transplant. 2009;24:1587-92.
20. Rahmani E, Samimi M, Ebrahimi FA, et al. The effects of 
omega-3 fatty acids and vitamin E co-supplementation on 
gene expression of lipoprotein(a) and oxidized low-density 
lipoprotein, lipid profiles and biomarkers of oxidative 
stress in patients with polycystic ovary syndrome. Mol Cell 
Endocrinol. 2017;439:247-55.
21. Farvid MS, Siassi F, Jalali M, Hosseini M, Saadat N. The 
impact of vitamin and/or mineral supplementation on 
lipid profiles in type 2 diabetes. Diabetes Res Clin Pract. 
2004;65:21-8.
22. Leonard SW, Joss JD, Mustacich DJ, Blatt DH, Lee YS, 
Traber MG. Effects of vitamin E on cholesterol levels of 
hypercholesterolemic patients receiving statins. Am J 
Health Syst Pharm. 2007;64:2257-66.
23. Tolonen N, Forsblom C, Thorn L, et al. Relationship 
between lipid profiles and kidney function in patients with 
type 1 diabetes. Diabetologia. 2008;51:12-20.
24. Chaturvedi N, Fuller JH, Taskinen MR. Differing 
associations of lipid and lipoprotein disturbances with the 
macrovascular and microvascular complications of type 1 
diabetes. Diabetes Care. 2001;24:2071-7.
25. Venugopal SK, Devaraj S, Yang T, Jialal I. Alpha-
tocopherol decreases superoxide anion release in human 
monocytes under hyperglycemic conditions via inhibition 
of protein kinase C-alpha. Diabetes. 2002;51:3049-54.
26. Landrier JF, Gouranton E, El Yazidi C, et al. Adiponectin 
expression is induced by vitamin E via a peroxisome 
proliferator-activated receptor gamma-dependent 
mechanism. Endocrinology. 2009;150:5318-25.
27. Gupta S, Sharma TK, Kaushik GG, Shekhawat VP. 
Vitamin E supplementation may ameliorate oxidative 
stress in type 1 diabetes mellitus patients. Clin Lab. 
2011;57:379-86.
28. Naziroglu M, Akkus S, Soyupek F, et al. Vitamins C and 
E treatment combined with exercise modulates oxidative 
stress markers in blood of patients with fibromyalgia: a 
controlled clinical pilot study. Stress. 2010;13:498-505.
29. Karajibani M, Hashemi M, Montazerifar F, Dikshit M. Effect 
of vitamin E and C supplements on antioxidant defense 
system in cardiovascular disease patients in Zahedan, 
southeast Iran. J Nutr Sci Vitaminol (Tokyo). 2010;56:436-
40.
30. Kasperczyk S, Dobrakowski M, Kasperczyk A, et al. 
alpha-Tocopherol supplementation and the oxidative 
stress, homocysteine, and antioxidants in lead exposure. 
Arch Environ Occup Health. 2017;72:153-8.
31. Nadeem A, Raj HG, Chhabra SK. Effect of vitamin 
E supplementation with standard treatment on oxidant-
antioxidant status in chronic obstructive pulmonary 
disease. Indian J Med Res. 2008;128:705-11.
32. Aghadavod E, Khodadadi S, Baradaran A, Nasri P, 
Bahmani M, Rafieian-Kopaei M. Role of Oxidative Stress 
and Inflammatory Factors in Diabetic Kidney Disease. Iran 
J Kidney Dis. 2016;10:337-43.
Correspondence to:
Zatollah Asemi
Research Center for Biochemistry and Nutrition in Metabolic 
Diseases, Kashan University of Medical Sciences, Kashan, Iran
Tel: +98 31 5546 3378
Fax: +98 31 5546 3377
E-mail: asemi_r@yahoo.com
Received October 2017
Revised December 2017
Accepted December 2017
